Core Viewpoint - Benitec Biopharma Inc. (BNTC) is focused on developing BB-301, a genetic medicine aimed at treating OPMD-related dysphagia, a progressive condition that can lead to severe complications [1]. Group 1: Company Overview - Benitec Biopharma Inc. is a clinical-stage company specializing in genetic medicine [1]. - The lead asset, BB-301, targets a specific medical condition related to OPMD [1]. Group 2: Educational Background of Key Personnel - Myriam Hernandez Alvarez holds multiple degrees, including an Electronics and Telecommunication Engineering degree, a M.Sc. in computer science, a graduate degree in Business Management, and a Ph.D. in computer applications [1].

急性髓系白血病 （AML） 由多种突变引发，但其最具侵袭性的驱动因素仍不明确。 2026 年 1 月 29 日，复旦大学代谢与整合生物学研究院/ 郑州大学天健先进生物医学实验室 叶浩彬 团队 （ 复旦大学 贾昂 博士、 张潇文 博士 生、深圳市人民医院 周继豪 教授为论文共同第一作者 ） ，在 Cell Metabolism 期刊发表了题为： Dual Targeting of SLC25A51 and Succinate Dehydrogenase Selectively Depletes Mitochondrial NAD+to Eradicate KRAS-Driven AML 的研究论文。 该研究通过双重靶向线粒体 NAD + 转运蛋白 SLC25A51 和 琥珀酸脱氢酶 （SDH） ，选择性耗竭线粒体 NAD + ，从而根除 KRAS 驱动的 急性髓系 白血病 （AML） ，为基于代谢脆弱性的治疗提供了新范式。 撰文丨王聪 编辑丨王多鱼 排版丨水成文 总的来说，该研究揭示了 KRAS 特异性代谢脆弱性，并提出针对 KRAS 驱动型 急性髓系白血病 （AML） 的双重抑制疗法。 论文链接 ： 在这项最 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 一、本期业绩预告情况 （一）业绩预告期间 2025年1月1日至2025年12月31日。 2024年度每股亏损2.73元。 （二）业绩预告情况 （1）经荣昌生物制药（烟台）股份有限公司（以下简称"公司"）财务部门初步测算，预计2025年度营 业收入约325,000万元，与上年同期相比，将增加收入约153,314万元，同比增加约89%。 （2）公司预计2025年度实现归属于母公司所有者的净利润约71,600万元，与上年同期相比，实现扭亏 为盈。 （3）公司预计2025年度归属于母公司所有者扣除非经常性损益后的净利润约7,850万元，与上年同期相 比，实现扭亏为盈。 （三）本期业绩预告相关的财务数据未经注册会计师预审计。 二、上年同期业绩情况 2024年度营业收入171,686.17万元。 2024年度实现归属于母公司所有者的净亏损146,836.08万元。 2024年度归属于母公司所有者扣除非经常性损益后的净亏损150,764.24万元。 三、本期业绩变化的主要原因 （一）主营业 ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Chairman of Meuhedet, Israel’s third-largest health fundTORONTO and HAIFA, Israel, Jan. 30, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) today announced changes to its board of directors (the “Board”). Effective today, Mr. Eyal Gabbai has been appointed to the Board replacing Dr. Gadi Riesenfeld, who has resigned from the Board. Dr. Riesenfeld will continue to support NurExone as a member of the Company’s Scientific Advisory Board. The C ...

Live Chat on The Biotech Forum sees frequent discussion of specific covered call trades. To see what covered call trades I am currently executing along with a model portfolio of attractive biotech stocks, just initiate your free trial into The Biotech Forum by clicking HERE .The market had a bit of a 'hiccup' in early trading on Thursday. However, after declining nearly 2.5% in the first hour of trading, the NASDAQ clawed back most of those early losses to end Thursday just over .7% inBret Jensen has over 1 ...

Core Viewpoint - A class action lawsuit has been filed against Vistagen Therapeutics, Inc. for allegedly providing misleading information regarding its Phase 3 PALISADE-3 trial of fasedienol, leading to significant investor losses [2][7]. Group 1: Lawsuit Details - The lawsuit is on behalf of all individuals and entities who purchased Vistagen common stock between April 1, 2024, and December 16, 2025, inclusive [2]. - Investors have until March 16, 2026, to apply to the Court to be appointed as lead plaintiff in the lawsuit [2]. Group 2: Allegations - The complaint alleges that Vistagen made overwhelmingly positive statements while concealing material adverse facts about the Phase 3 PALISADE-3 trial [7]. - On December 17, 2025, Vistagen announced that the PALISADE-3 study did not show a statistically significant improvement on its primary endpoint, leading to a dramatic stock price decline from $4.36 to $0.86, a drop of over 80% [7]. Group 3: Next Steps for Investors - Investors who suffered losses or have information regarding the case are encouraged to contact Bragar Eagel & Squire for further assistance [4].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Corcept Therapeutics Incorporated due to allegations of materially misleading business information issued to the investing public [1] Company Summary - Corcept Therapeutics Incorporated is facing scrutiny for potentially misleading information that may have affected its securities [1] - Shareholders who purchased Corcept securities may be entitled to compensation without any out-of-pocket fees or costs through a contingency fee arrangement [1]

Financial Data and Key Metrics Changes - The preliminary results of the voting indicated that the compensation of the named executive officer was approved on an advisory basis [12] - The appointment of MaloneBailey, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, was ratified [13] Business Line Data and Key Metrics Changes - No specific financial data or key metrics related to business lines were provided in the meeting [2][3] Market Data and Key Metrics Changes - No specific market data or key metrics were discussed during the meeting [2][3] Company Strategy and Development Direction - The company is focused on good corporate practices, as evidenced by the advisory vote on executive compensation and the ratification of the auditor's appointment [10][11] Management Comments on Operating Environment and Future Outlook - Management noted that forward-looking statements regarding future events or financial performance involve risks and uncertainties, and actual results could differ materially from predictions [14] Other Important Information - The meeting was held virtually, and all necessary procedures for voting and quorum were followed [5][6] - The company emphasized the importance of investor sentiment regarding executive compensation [9][10] Q&A Session Summary - No questions were submitted by stockholders during the Q&A session, leading to the conclusion of the meeting [15]

Financial Data and Key Metrics Changes - The preliminary results of the voting indicated that the compensation of the named executive officer has been approved on an advisory basis [12] - The appointment of MaloneBailey, LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2026, has been ratified [13] Business Line Data and Key Metrics Changes - No specific data or metrics related to individual business lines were discussed during the meeting Market Data and Key Metrics Changes - No specific market data or metrics were provided in the meeting Company Strategy and Development Direction and Industry Competition - The company is focused on good corporate practices, as evidenced by the advisory vote on executive compensation and the ratification of the independent auditor [11] Management's Comments on Operating Environment and Future Outlook - Management noted that forward-looking statements regarding future events or financial performance involve risks and uncertainties, and actual results could differ materially from predictions [14] Other Important Information - The meeting was held virtually, and all necessary procedures for voting and quorum were followed [5][6] - The company emphasized the importance of stockholder participation and the advisory nature of certain proposals [9][10] Q&A Session Summary - No questions were submitted by stockholders during the Q&A session, leading to the conclusion of the meeting without any inquiries [15]